- Home
- PROK vs LXRX Comparison
PROK vs LXRX Comparison
Compare PROK & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | LXRX |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.1M | 447.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | PROK | LXRX |
|---|---|---|
| Price | $2.48 | $1.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $7.40 | $3.23 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $744,000.00 | ★ $70,864,000.00 |
| Revenue This Year | $956.51 | $56.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1255.21 |
| 52 Week Low | $0.46 | $0.28 |
| 52 Week High | $7.13 | $1.66 |
Technical Indicators
Market Signals| Indicator | PROK | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 40.21 |
| Support Level | $2.10 | $1.12 |
| Resistance Level | $2.29 | $1.24 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 76.53 | 24.39 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.